CRBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Corbus Pharmaceuticals Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$4.46−0.06 (-1.33%)
Close on Oct 19, 2026
- Market cap
- $86.56M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
71.4%
14M of 19M shares
Institutional holders
107
24 new, 23 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
3 buys · 14 sales
Net sold $1.00M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Octagon Capital Advisors LP | 955,000 | 5.40% | 13G (passive) amendment | Dec 31, 2025 |
| Adage Capital Partners GP, L.L.C. | 796,392 | 7.70% | 13G (passive) | Feb 2, 2024 |
| OrbiMed Capital LLC | 718,200 | 5.90% | 13G (passive) amendment | Dec 31, 2024 |
| Tang Capital Partners, LP | 426,220 | 9.60% | 13G (passive) | Jan 26, 2024 |
| Bihua Chen | 2,375,000 | 12.82% | 13G (passive) amendment | Nov 3, 2025 |
| Chen Bihua | 2,344,971 | 13.36% | 13G (passive) amendment | Dec 11, 2025 |
| Peter Kolchinsky | 1,914,788 | 9.90% | 13G (passive) | Sep 23, 2026 |
| Cormorant Global Healthcare GP, LLC | 1,475,000 | – | 13G (passive) | Jan 26, 2024 |
| abrdn Inc. | 1,321,750 | 7.53% | 13G (passive) | Dec 31, 2025 |
| BlackRock, Inc. | 1,093,434 | 5.90% | 13G (passive) | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CRBP | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Cormorant Asset Management, LP | 2,344,971 | 12.12% | $22.00M | – | 1.13% |
| Orbimed Advisors LLC | 1,737,287 | 8.98% | $16.30M | – | 0.30% |
| BlackRock, Inc. | 1,331,135 | 6.88% | $12.49M | +1,059,499 | 0.00% |
| abrdn plc | 1,321,750 | 6.83% | $12.40M | – | 0.02% |
| Vanguard Capital Management LLC | 760,940 | 3.93% | $7.14M | +26,834 | 0.00% |
| Jones Hill Capital LP | 653,572 | 3.38% | $6.13M | New | 1.30% |
| Prosight Management, LP | 650,000 | 3.36% | $6.10M | −47,108 | 1.05% |
| Stonepine Capital Management, LLC | 425,000 | 2.20% | $3.99M | +41,538 | 2.25% |
| Geode Capital Management, LLC | 423,374 | 2.19% | $3.97M | +236,345 | 0.00% |
| ADAR1 Capital Management, LLC | 421,787 | 2.18% | $3.96M | +90,006 | 0.18% |
| Diadema Partners LP | 301,264 | 1.56% | $2.83M | −138,693 | 0.36% |
| Susquehanna International Group, Llp | 293,203 | 1.52% | $2.75M | −40,212 | 0.00% |
| State Street Corp | 254,672 | 1.32% | $2.39M | +185,800 | 0.00% |
| Dimensional Fund Advisors LP | 190,214 | 0.98% | $1.78M | +53,612 | 0.00% |
| Exome Asset Management LLC | 184,914 | 0.96% | $1.73M | −49,222 | 1.07% |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 151,640 | 0.78% | $1.42M | −8,822 | 0.00% |
| Jane Street Group, LLC | 139,133 | 0.72% | $1.31M | +65,940 | 0.00% |
| Northern Trust Corp | 124,906 | 0.65% | $1.17M | +83,402 | 0.00% |
| Vanguard Fiduciary Trust Co | 112,397 | 0.58% | $1.05M | +16,156 | 0.00% |
| Vanguard Portfolio Management LLC | 111,302 | 0.58% | $1.04M | +86,937 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 107 | 14M | 71.4% | 24 / 29 | 26 / 23 | 4M | 3M |
| Q1 2026 | 107 | 13M | 66.3% | 24 / 33 | 22 / 13 | 3M | 2M |
| Q4 2025 | 101 | 13M | 68.9% | 29 / 25 | 23 / 9 | 6M | 1M |
| Q3 2025 | 81 | 9M | 45.5% | 16 / 16 | 25 / 15 | 1M | 1M |
| Q2 2025 | 80 | 9M | 46.9% | 15 / 17 | 29 / 21 | 1M | 2M |
| Q1 2025 | 86 | 10M | 53.9% | 17 / 23 | 24 / 29 | 2M | 2M |
| Q4 2024 | 99 | 11M | 56.6% | 21 / 34 | 22 / 26 | 2M | 2M |
| Q3 2024 | 107 | 12M | 60.8% | 31 / 39 | 20 / 30 | 5M | 3M |
| Q2 2024 | 107 | 11M | 55.6% | 41 / 23 | 24 / 15 | 4M | 2M |
| Q1 2024 | 82 | 9M | 46.2% | 52 / 15 | 6 / 3 | 8M | 0M |
| Q4 2023 | 34 | 1M | 3.9% | 8 / 4 | 7 / 1 | 0M | 0M |
| Q3 2023 | 27 | 1M | 3.8% | 3 / 7 | 5 / 3 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of CRBP | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 533,575 | 2.76% | $5.00M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 406,966 | 2.10% | $3.82M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 208,310 | 1.08% | $1.95M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 179,556 | 0.93% | $1.61M | 0.00% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 157,182 | 0.81% | $1.47M | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 83,288 | 0.43% | $658.81K | 0.00% | May 31, 2026 |
| Dimensional U.S. Small Cap ETF | 58,383 | 0.30% | $523.70K | 0.00% | Jul 31, 2026 |
| iShares Micro-Cap ETF | 55,352 | 0.29% | $519.20K | 0.03% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 39,702 | 0.21% | $356.13K | 0.00% | Jul 31, 2026 |
| U.S. Micro Cap Portfolio | 31,546 | 0.16% | $282.97K | 0.00% | Jul 31, 2026 |
| Master Small Cap Index Series | 30,772 | 0.16% | $288.64K | 0.00% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 27,193 | 0.14% | $215.10K | 0.00% | May 31, 2026 |
| U.S. Small Cap Portfolio | 26,811 | 0.14% | $240.49K | 0.00% | Jul 31, 2026 |
| Fidelity Series Total Market Index Fund | 23,576 | 0.12% | $186.49K | 0.00% | May 31, 2026 |
| Fidelity Small Cap Value Index Fund | 23,002 | 0.12% | $215.76K | 0.01% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Yuval Cohen | Chief Executive Officer, Director | 157,316 | 0.81% | Aug 10, 2026 |
| Leonardo Viana Nicacio | Chief Medical Officer | 58,333 | 0.30% | Aug 17, 2026 |
| Nishant C. Saxena | Chief Business Officer | 77,900 | 0.40% | Aug 12, 2026 |
| Sean F. Moran | Chief Financial Officer | 84,694 | 0.44% | Aug 10, 2026 |
| Dominic Smethurst | Chief Medical Officer | 89,790 | 0.46% | Mar 4, 2026 |
| Ian Hodgson | Chief Operating Officer | 51,080 | 0.26% | Feb 18, 2026 |
| Yong Ben | Director | 9,383 | 0.05% | Sep 15, 2026 |
| John Kenneth Jenkins | Director | 3,833 | 0.02% | Jun 11, 2026 |
| Anne Altmeyer | Director | 7,579 | 0.04% | Jun 11, 2026 |
| Winston Kung | Director | 12,140 | 0.06% | Jun 11, 2026 |
| Brent Pfeiffenberger | Director | 7,500 | 0.04% | May 21, 2026 |
| Rachelle Suzanne Jacques | Director | 11,383 | 0.06% | May 21, 2026 |
| Alan F. Holmer | Director | 10,629 | 0.05% | Jun 2, 2025 |
| Bihua Chen | 10% owner | 2,344,971 | 12.12% | Dec 15, 2025 |
| Cormorant Asset Management, LP | 10% owner | 1,475,000 | 7.63% | Dec 15, 2025 |
| Cormorant Global Healthcare Master Fund, LP | 10% owner | 2,349,231 | 12.15% | Dec 15, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Yong Ben Director | Sep 14, 2026 | Sale(10b5-1 plan) | −2,000 | $7.84 | $15.68K | 9,383 |
| Leonardo Viana Nicacio Chief Medical Officer | Aug 16, 2026 | Award | +58,333 | – | – | 58,333 |
| Nishant C. Saxena Chief Business Officer | Aug 11, 2026 | Buy | +2,600 | $9.63 | $25.04K | 77,900 |
| Yuval Cohen Chief Executive Officer, Director | Aug 7, 2026 | Sale(10b5-1 plan) | −17,000 | $10.08 | $171.36K | 157,316 |
| Sean F. Moran Chief Financial Officer | Aug 7, 2026 | Sale(10b5-1 plan) | −12,000 | $10.08 | $120.96K | 84,694 |
| Anne Altmeyer Director | Jun 10, 2026 | Sale(10b5-1 plan) | −2,412 | $7.91 | $19.08K | 7,579 |
| John Kenneth Jenkins Director | Jun 10, 2026 | Sale(10b5-1 plan) | −4,800 | $7.91 | $37.97K | 3,833 |
| Winston Kung Director | Jun 10, 2026 | Sale(10b5-1 plan) | −2,026 | $7.91 | $16.03K | 12,140 |
| Nishant C. Saxena Chief Business Officer | Jun 3, 2026 | Buy | +9,000 | $7.58 | $68.22K | 75,300 |
| Nishant C. Saxena Chief Business Officer | Jun 2, 2026 | Buy | +4,500 | $7.33 | $32.99K | 66,300 |
| Nishant C. Saxena Chief Business Officer | May 21, 2026 | Award | +58,300 | – | – | 61,800 |
| Anne Altmeyer Director | May 19, 2026 | Award | +3,800 | – | – | 9,991 |
| John Kenneth Jenkins Director | May 19, 2026 | Award | +3,800 | – | – | 8,633 |
| Yong Ben Director | May 19, 2026 | Award | +3,800 | – | – | 11,383 |
| Winston Kung Director | May 19, 2026 | Award | +3,800 | – | – | 14,166 |
| Rachelle Suzanne Jacques Director | May 19, 2026 | Award | +3,800 | – | – | 11,383 |
| Brent Pfeiffenberger Director | May 19, 2026 | Award | +7,500 | – | – | 7,500 |
| Dominic Smethurst Chief Medical Officer | Mar 2, 2026 | Sale | −6,097 | $8.30 | $50.61K | 89,790 |
| Ian Hodgson Chief Operating Officer | Feb 17, 2026 | Sale | −847 | $7.38 | $6.25K | 51,080 |
| Sean F. Moran Chief Financial Officer | Feb 13, 2026 | Sale(10b5-1 plan) | −4,701 | $7.78 | $36.57K | 96,694 |
| Yuval Cohen Chief Executive Officer, Director | Feb 13, 2026 | Sale(10b5-1 plan) | −13,871 | $7.78 | $107.92K | 174,316 |
| Dominic Smethurst Chief Medical Officer | Feb 3, 2026 | Sale | −3,285 | $8.09 | $26.58K | 95,887 |
| Ian Hodgson Chief Operating Officer | Feb 3, 2026 | Sale | −2,415 | $8.09 | $19.54K | 51,927 |
| Yuval Cohen Chief Executive Officer, Director | Jan 14, 2026 | Award | +50,000 | – | – | 188,187 |
| Ian Hodgson Chief Operating Officer | Jan 14, 2026 | Award | +28,365 | – | – | 54,342 |
| Sean F. Moran Chief Financial Officer | Jan 14, 2026 | Award | +28,082 | – | – | 101,395 |
| Dominic Smethurst Chief Medical Officer | Jan 14, 2026 | Award | +28,365 | – | – | 99,172 |
| Bihua Chen 10% owner | Dec 11, 2025 | Sale | −30,029 | $11.46 | $344.13K | 2,344,971 |
| Yuval Cohen Chief Executive Officer, Director | Oct 27, 2025 | Option exercise | +8,973 | $4.26 | $38.22K | 147,160 |
| Yuval Cohen Chief Executive Officer, Director | Oct 27, 2025 | Sale(10b5-1 plan) | −8,973 | $17.14 | $153.80K | 138,187 |
| Sean F. Moran Chief Financial Officer | Oct 24, 2025 | Option exercise | +12,981 | $4.26 | $55.30K | 86,294 |
| Sean F. Moran Chief Financial Officer | Oct 24, 2025 | Sale(10b5-1 plan) | −12,981 | $17.02 | $220.94K | 73,313 |
| Yuval Cohen Chief Executive Officer, Director | Oct 24, 2025 | Option exercise | +18,660 | $4.26 | $79.49K | 156,847 |
| Yuval Cohen Chief Executive Officer, Director | Oct 24, 2025 | Sale(10b5-1 plan) | −18,660 | $17.01 | $317.41K | 138,187 |
| Anne Altmeyer Director | Oct 20, 2025 | Sale(10b5-1 plan) | −1,060 | $20.50 | $21.73K | 6,191 |
| Anne Altmeyer Director | Oct 20, 2025 | Option exercise | +1,060 | $4.80 | $5.09K | 7,251 |
| Yong Ben Director | May 30, 2025 | Award | +4,800 | – | – | 7,583 |
| Anne Altmeyer Director | May 30, 2025 | Award | +4,800 | – | – | 6,191 |
| Anne Altmeyer Director | May 30, 2025 | Sale(10b5-1 plan) | −1,392 | $7.25 | $10.09K | 1,391 |
| Winston Kung Director | May 30, 2025 | Award | +4,800 | – | – | 10,366 |
| Alan F. Holmer Director | May 30, 2025 | Award | +4,800 | – | – | 10,629 |
| Rachelle Suzanne Jacques Director | May 30, 2025 | Award | +4,800 | – | – | 7,583 |
| John Kenneth Jenkins Director | May 30, 2025 | Sale(10b5-1 plan) | −2,783 | $7.35 | $20.46K | 33 |
| John Kenneth Jenkins Director | May 30, 2025 | Award | +4,800 | – | – | 4,833 |
| Dominic Smethurst Chief Medical Officer | Mar 6, 2025 | Sale | −6,393 | $6.78 | $43.34K | 70,807 |
| Yuval Cohen Chief Executive Officer, Director | Feb 14, 2025 | Sale(10b5-1 plan) | −7,134 | $8.76 | $62.49K | 138,187 |
| Sean F. Moran Chief Financial Officer | Feb 14, 2025 | Sale(10b5-1 plan) | −2,792 | $8.76 | $24.46K | 73,313 |
| Yuval Cohen Chief Executive Officer, Director | Jan 31, 2025 | Award | +68,100 | – | – | 145,321 |
| Sean F. Moran Chief Financial Officer | Jan 31, 2025 | Award | +27,500 | – | – | 76,105 |
| Dominic Smethurst Chief Medical Officer | Jan 31, 2025 | Award | +27,200 | – | – | 77,200 |
| Cormorant Global Healthcare Master Fund, LP 10% owner | Sep 20, 2024 | Buy | +47,564 | $21.47 | $1.02M | 2,349,231 |
| Cormorant Global Healthcare Master Fund, LP 10% owner | Sep 20, 2024 | Buy | +66,088 | $19.61 | $1.30M | 2,162,116 |
| Cormorant Global Healthcare Master Fund, LP 10% owner | Sep 20, 2024 | Buy | +139,551 | $20.42 | $2.85M | 2,301,667 |
| Cormorant Global Healthcare Master Fund, LP 10% owner | Sep 20, 2024 | Buy | +25,769 | $22.23 | $572.84K | 2,375,000 |
| Cormorant Global Healthcare Master Fund, LP 10% owner | Sep 20, 2024 | Buy | +45,085 | $17.48 | $788.09K | 2,070,085 |
| Cormorant Global Healthcare Master Fund, LP 10% owner | Sep 20, 2024 | Buy | +25,943 | $18.36 | $476.31K | 2,096,028 |
| Winston Kung Director | Aug 16, 2024 | Award | +5,566 | – | – | 5,566 |
| Yuval Cohen Chief Executive Officer, Director | Jun 18, 2024 | Sale(10b5-1 plan) | −7,179 | $42.24 | $303.24K | 77,221 |
| Yuval Cohen Chief Executive Officer, Director | Jun 18, 2024 | Option exercise | +1,770 | $14.10 | $24.96K | 86,170 |
| Yuval Cohen Chief Executive Officer, Director | Jun 18, 2024 | Sale(10b5-1 plan) | −1,770 | $42.24 | $74.76K | 84,400 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Stifel, Nicolaus & Company, Inc CIAS /FA Officer | Aug 7, 2026 | 17,000 | $171.40K | Aug 7, 2026 | Restricted Stock Units |
| Stifel, Nicolaus & Company, Inc CIAS /FA Officer | Aug 7, 2026 | 12,000 | $120.97K | Aug 7, 2026 | Restricted Stock Units |
| Dominic Smethurst Officer | Jul 27, 2026 | 23,025 | $211.82K | Jul 27, 2026 | Restricted Stock Units |
| Dominic Smethurst Officer | Mar 2, 2026 | 6,097 | $50.60K | Mar 2, 2026 | Restricted Stock Units |
| Yuval Cohen Officer | Feb 13, 2026 | 20,000 | $812.60K | Feb 13, 2026 | Restricted Stock Units |
| Yuval Cohen Officer | Oct 24, 2025 | 27,633 | $469.98K | Oct 24, 2025 | Stock Option Exercise |
| Sean F. Moran Officer | Oct 24, 2025 | 12,981 | $220.92K | Oct 24, 2025 | Stock Option Exercise |
| Dominic Smethurst Officer | Mar 6, 2025 | 6,393 | $43.73K | Mar 6, 2025 | Restricted Stock Units |
| Sean F. Moran Officer | Feb 14, 2025 | 2,792 | $26.47K | Feb 14, 2025 | Restricted Stock Units |
| Yuval Cohen Officer | Feb 14, 2025 | 7,134 | $67.63K | Feb 14, 2025 | Restricted Stock Units |
| Avery W. Catlin Director | Sep 4, 2024 | 888 | $50.11K | Sep 4, 2024 | Option Exercise |
| Sean F. Moran Officer | Jun 14, 2024 | 18,043 | $954.29K | Jun 14, 2024 | Options |
| Yuval Cohen Officer | Jun 14, 2024 | 63,358 | $3.35M | Jun 14, 2024 | Owned Shares |
| Rachael Louise Brake Former Chief Scientific Officer | May 8, 2024 | 15,550 | $634.88K | May 8, 2024 | Option Exercise |